E-viri
PDF
Recenzirano
Odprti dostop
-
El Sahly, Hana M; Baden, Lindsey R; Essink, Brandon; Doblecki-Lewis, Susanne; Martin, Judith M; Anderson, Evan J; Campbell, Thomas B; Clark, Jesse; Jackson, Lisa A; Fichtenbaum, Carl J; Zervos, Marcus; Rankin, Bruce; Eder, Frank; Feldman, Gregory; Kennelly, Christina; Han-Conrad, Laurie; Levin, Michael; Neuzil, Kathleen M; Corey, Lawrence; Gilbert, Peter; Janes, Holly; Follmann, Dean; Marovich, Mary; Polakowski, Laura; Mascola, John R; Ledgerwood, Julie E; Graham, Barney S; August, Allison; Clouting, Heather; Deng, Weiping; Han, Shu; Leav, Brett; Manzo, Deb; Pajon, Rolando; Schödel, Florian; Tomassini, Joanne E; Zhou, Honghong; Miller, Jacqueline
The New England journal of medicine, 11/2021, Letnik: 385, Številka: 19Journal Article
The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.
